Compare Globus Medical Inc. Class A Common Stock (GMED) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

XRAY trades at $8.44, down 1.06% on the day and near its 52-week low, reflecting persistent bearish technical signals. The company reported a net loss of $598 million in 2025, with negative profit margins and declining revenue, though Q2 2026 earnings beat expectations. Debt-to-asset ratio has risen to 42.88% in 2025, indicating increased financial leverage amid ongoing restructuring efforts.

The outlook remains challenging with weak profitability and high debt, but analyst consensus suggests potential upside to a $13.00 price target. Key risks include margin pressure, competitive threats, and execution of the turnaround plan. Investment appeal hinges on successful operational improvements and sustained earnings recovery.